help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on January 3, 2008
Endocrinology, doi:10.1210/en.2007-0844
A more recent version of this article appeared on April 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
149/4/1890    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bentov, I.
Right arrow Articles by Werner, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bentov, I.
Right arrow Articles by Werner, H.

Submitted on June 25, 2007
Accepted on December 27, 2007

Insulin-like growth factor-1 regulates KLF6 gene expression in a p53-dependent manner

Itay Bentov, Goutham Narla, Hagit Schayek, Kuhihara Akita, Stephen R. Plymate, Derek LeRoith, Scott L. Friedman, and Haim Werner*

Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel (I.B., H.S., H.W.); Division of Liver Diseases (G.N., K.A., S.L.F.) and Division of Endocrinology and Diabetes (D.L.), Mount Sinai School of Medicine, New York, New York 10029 USA; and Department of Medicine, University of Washington, Seattle, Washington 98195 (S.R.P.)

* To whom correspondence should be addressed. E-mail: hwerner{at}post.tau.ac.il.

High circulating IGF-1 concentrations are associated with an increased risk for breast, prostate, and colorectal cancer. Kruppel-like factor-6 (KLF6) is a zinc finger tumor suppressor inactivated in prostate and other types of cancer. We have previously demonstrated that KLF6 is a potent transactivator of the IGF-1 receptor (IGF-1R) promoter. The aim of the present study was to examine the potential regulation of KLF6 gene expression by IGF-1. The human colon cancer cell lines HCT116 +/+ and - (with normal and disrupted p53, respectively) were treated with IGF-1. Western blots, qRT-PCR, and transfection assays were used to evaluate the effect of IGF-1 on KLF-6 production. Signaling pathway inhibitors were used to identify the mechanisms responsible for regulation of KLF6 expression. SiRNA against p53 and KLF6 were used to assess the role of p53 in regulation of KLF6 expression by IGF-1 and to evaluate KLF6 involvement in cell cycle control. Results obtained showed that IGF-1 stimulated KLF-6 transcription in cells with normal, but not disrupted, p53, suggesting that KLF6 is a downstream target for IGF-1 action. Stimulation of KLF6 expression by IGF-1 in a p53-dependent manner may constitute a novel mechanism of action of IGF-1, with implications in normal cell cycle progression and cancer biology.


Key words: IGF-1 • KLF6 • p53 • transcription • tumor suppressor







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society